Press release
Investigation announced for Investors in Exscientia plc (NASDAQ: EXAI) over possible Violations of Securities Laws
An investigation for investors in Exscientia plc (NASDAQ: EXAI) shares over potential securities laws violations by Exscientia plc
Investors who purchased shares of Exscientia plc (NASDAQ: EXAI), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Exscientia plc (NASDAQ: EXAI) concerning whether a series of statements by Exscientia plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
United Kingdom based Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs.
On February 13, 2024, Exscientia plc announced the termination of Andrew Hopkins as the company's Chief Executive Officer and Principal Executive Officer, as well as his removal as an Executive Director of the Board, effective immediately and for cause. This decision by the Board of Directors was made following an investigation that revealed Dr. Hopkins had engaged in inappropriate relationships with two employees, which were deemed inconsistent with the company's standards and values.
Further details emerged as a special committee of the board enlisted outside counsel to investigate the alleged conduct of the executive. The inquiry uncovered, per news reports, that David Nicholson, the board chairman, had prior knowledge of one of Hopkins' relationships and addressed it independently with outside counsel, rather than consulting with the board. Subsequently, after discussions with other board members, Nicholson resigned from his board position.
Shares of Exscientia plc (NASDAQ: EXAI) declined from $7.91 per share on February 12, 2024, to $4.33 per share on April 15, 2024.
Those who purchased shares of Exscientia plc (NASDAQ: EXAI) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Exscientia plc (NASDAQ: EXAI) over possible Violations of Securities Laws here
News-ID: 3466178 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation announced for Investors who lost money with Legend Biotech Corpora …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Legend Biotech Corporation.
Investors who purchased shares of Legend Biotech Corporation (NASDAQ: LEGN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Legend Biotech Corporation directors breached their fiduciary duties and caused damage to the company and its shareholders.
Somerset,…
Lawsuit Alert: Investors who lost money with shares of Sprout Social, Inc. (NASD …
An investor, who purchased shares of Sprout Social, Inc. (NASDAQ: SPT), filed a lawsuit over alleged violations of Federal Securities Laws by Sprout Social, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sprout Social, Inc. (NASDAQ: SPT) have certain options and for certain investors are short and strict deadlines running. Deadline: July 12, 2024. NASDAQ: SPT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Investors in shares of Brainstorm Cell Therapeutics …
An investigation was announced for long-term investors in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) concerning potential breaches of fiduciary duties by certain directors of Brainstorm Cell Therapeutics Inc.
Investors who are current long term investors in Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
Lawsuit filed for Investors who lost money with shares of Altimmune, Inc. (NASDA …
An investor, who purchased shares of Altimmune, Inc. (NASDAQ: ALT), filed a lawsuit over alleged violations of Federal Securities Laws by Altimmune, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and for certain investors are short and strict deadlines running. Deadline: July 5, 2024. NASDAQ: ALT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
More Releases for Exscientia
AI for Pharma and Biotech Market 2022-29 Analysis with Competitors: Cyclica Inc, …
The AI for Pharma and Biotech report presents information related to restraints, key drivers, and opportunities, along with a detailed global market share analysis. The current market is quantitatively analyzed from 2022 to 2029 to highlight the global market growth scenario. The competitive landscape comprises key players, strategies, and new developments in the upcoming years.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=6143768
Top Key Players are covered in this report: Cyclica Inc, Cloud…
Artificial Intelligence in Drug Discovery Market Analysis, Technical Study and B …
Report Ocean releases its latest report on the global Artificial Intelligence in Drug Discovery Market. A combination of information gathered from first-hand sources, qualitative and quantitative assessments of industry analysts, and insights from experts and participants across the value chain is used to calculate the global Artificial Intelligence in Drug Discovery Market.
The global artificial intelligence (AI) in drug discovery market size is expected to reach USD 4.13 billion by 2028…
AI In Pharmaceutical Market May See a Big Move | Major Giants Exscientia, Sanofi …
The Latest research study released by HTF MI “Worldwide Ai In Pharmaceutical Market” with 100+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Some of the Major Companies covered in this…
AI Drug Development Market Outlook 2021: Big Things are Happening | Insilico Med …
Global AI Drug Development Market Report 2020, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider AI Drug Development market, and compares it…
AI for Drug Discovery Market Insights to 2027 | Atomwise, Insilico Medicine, Num …
The AI for drug discovery market is expected to grow during the forecast period due to the increasing number of cross-industry partnerships & collaborations, a significant growth in venture capital investments, rise in importance of drug discovery and increase in funding of the R&D activities for the use of AI technology in the field of drug discovery. However, limited awareness, unwillingness among medical practitioners to adopt AI-based technologies, unclear regulatory…
AI for Drug Discovery Market Size, Strategy, Business Outlook to 2027 - Atomwise …
Drug discovery is the preliminary step in the process of a novel drug identification and its therapeutic target. Artificial intelligence (AI) is commonly used in the healthcare industry for drug discovery. Artificial intelligence technology has the ability to recognize drug targets, and play a significant role in drug design, discovery, identification and screening of molecules instantly and effectively. Drug discovery or new drug target are being estimated based on potency,…
